Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
US FDA lifts clinical hold on Novavax's combo COVID-flu shot
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
AOL1d
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
Business Insider9h
Novavax’s Market Share and Pipeline Uncertainties Lead to Sell Rating
J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter ...
Novavax to Participate in Jefferies London Healthcare Conference
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...
Business Insider10h
Novavax Advances Vaccine Strategy Amid Financial Shifts
Novavax ( (NVAX)) has released its Q3 earnings. Here is a breakdown of the information Novavax presented to its investors. Novavax, Inc., based in Gaithersburg, Maryland, is a global ...